Organisation paid for research Program year 2025 Source: CMS Open Payments

Acclaim Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,678,666

161 payments

Through program year 2025, Acclaim Clinical Research is reported as receiving $1,678,666 in research payments, across 161 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $132,410 85
2024 Research $954,098 56
2023 Research $225,757 12
2022 Research $366,401 8

Breakdown

Who paid Research payments · program years 2022–2025
  1. Braintree Laboratories, Inc. $745,468 30 payments
  2. Merck Sharp & Dohme Corporation $576,477 8 payments
  3. Boehringer Ingelheim International GmbH $136,679 79 payments
  4. Amgen Inc. $96,204 8 payments
  5. Moderna TX, Inc. $62,819 18 payments
  6. Novartis Pharmaceuticals Corporation $35,534 4 payments
  7. Pfizer Inc. $12,877 7 payments
  8. Boehringer Ingelheim Pharma GmbH & Co.KG $11,685 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $783 2 payments
  10. GRT US Holding, Inc. $140 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $745,468 30 payments
  2. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $560,924 6 payments
  3. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $95,646 53 payments
  4. ASCEND P3 AD Extension $54,241 2 payments
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $33,689 3 payments
  6. A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults $31,932 8 payments
  7. A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age $23,733 3 payments
  8. BI 456906 in NASH F2/F3 - pivotal trial $18,512 1 payment
  9. BI 456906 in NASH F4 - pivotal trial $18,512 1 payment
  10. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults $15,553 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record